Success Metrics

Clinical Success Rate

87.8%

Based on 36 completed trials

Completion Rate

88%(36/41)

Active Trials

2(4%)

Results Posted

83%(30 trials)

Terminated

5(10%)

Phase Distribution

Ph not_applicable

23%

Ph phase_1

13%

Ph phase_2

15%

Ph phase_3

Ph phase_4

25%

Ph early_phase_1

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution45 total trials

Early Phase 1First-in-human

5(11.1%)

Phase 1Safety & dosage

6(13.3%)

Phase 2Efficacy & side effects

7(15.6%)

Phase 3Large-scale testing

4(8.9%)

Phase 4Post-market surveillance

12(26.7%)

N/ANon-phased studies

11(24.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.7%

36 of 43 finished

Non-Completion Rate

16.3%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(36)

Terminated(7)

Other(3)

Detailed Status

Completed36

Terminated5

unknown3

Recruiting2

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.8%

Most Advanced

Phase 4

Trials by Phase

Early Phase 15 (11.1%)

Phase 16 (13.3%)

Phase 27 (15.6%)

Phase 34 (8.9%)

Phase 412 (26.7%)

N/A11 (24.4%)

Trials by Status

completed3675%

terminated510%

recruiting24%

withdrawn24%

unknown36%

Recent Activity

2 active trials

Showing 5 of 48

recruitingphase_1

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

NCT04604782

recruitingphase_4

Allograft Dysfunction in Heart Transplant

NCT03102125

completed

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

NCT03505736

completednot_applicable

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

NCT04316676

completedphase_1

Treat COVID-19 Patients With Regadenoson

NCT04606069

View all 48 trials

Clinical Trials (48)

Showing 20 of 48 trialsScroll for more

NCT04604782Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Recruiting

NCT03102125Phase 4

Allograft Dysfunction in Heart Transplant

Recruiting

NCT03505736

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

Completed

NCT04316676Not Applicable

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Completed

NCT04606069Phase 1

Treat COVID-19 Patients With Regadenoson

Completed

NCT00837369Phase 1

Regadenoson R-T Perfusion Imaging Trial

Completed

NCT01334918Phase 2

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

Completed

NCT00826280Phase 3

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Completed

NCT02130453Phase 4

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Completed

NCT04521569Early Phase 1

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Completed

NCT01842035Not Applicable

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Completed

NCT01026012Not Applicable

Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing

Completed

NCT03236311Phase 2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Terminated

NCT03170817

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

Completed

NCT00871260Phase 4

Stress Testing and Cardiac Magnetic Resonance

Completed

NCT01969916Not Applicable

Stress CT Perfusion in Patients With Chest Pain

Completed

NCT02589977Phase 4

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF